Amgen (AMGN) Share-based Compensation (2009 - 2026)

Amgen has reported Share-based Compensation for 18 years, with the latest figure at $247.0 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 19.9% year-over-year to $247.0 million in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 64.17% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 94.33% from the prior year.
• Share-based Compensation was $247.0 million for Q2 2026 at Amgen, up from $75.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $577.0 million in Q4 2025, with the low at -$241.0 million in Q2 2022.
• Average Share-based Compensation over 5 years is $178.1 million, with a median of $183.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation sank 315.18% in 2022, then jumped 4021.43% in 2025.
• Over 5 years, Share-based Compensation stood at $567.0 million in 2022, then tumbled by 59.08% to $232.0 million in 2023, then plunged by 93.97% to $14.0 million in 2024, then surged by 4021.43% to $577.0 million in 2025, then plunged by 57.19% to $247.0 million in 2026.
• The last three Share-based Compensation figures came in at $247.0 million (Q2 2026), $75.0 million (Q1 2026), and $577.0 million (Q4 2025), per Business Quant data.